FR2668164A1 - Immunoglobuline purifiee. - Google Patents

Immunoglobuline purifiee. Download PDF

Info

Publication number
FR2668164A1
FR2668164A1 FR9112738A FR9112738A FR2668164A1 FR 2668164 A1 FR2668164 A1 FR 2668164A1 FR 9112738 A FR9112738 A FR 9112738A FR 9112738 A FR9112738 A FR 9112738A FR 2668164 A1 FR2668164 A1 FR 2668164A1
Authority
FR
France
Prior art keywords
antibody
column
purified preparation
protein
campath
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9112738A
Other languages
English (en)
French (fr)
Other versions
FR2668164B1 (2
Inventor
Ramage Paul Ian Nicholas
Allen Geoffrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2668164(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of FR2668164A1 publication Critical patent/FR2668164A1/fr
Application granted granted Critical
Publication of FR2668164B1 publication Critical patent/FR2668164B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9112738A 1990-10-17 1991-10-16 Immunoglobuline purifiee. Granted FR2668164A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (2)

Publication Number Publication Date
FR2668164A1 true FR2668164A1 (fr) 1992-04-24
FR2668164B1 FR2668164B1 (2) 1995-04-14

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
FR9112738A Granted FR2668164A1 (fr) 1990-10-17 1991-10-16 Immunoglobuline purifiee.
FR9209998A Withdrawn FR2677997A1 (fr) 1990-10-17 1992-08-13 Immunoglobuline purifiee.

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR9209998A Withdrawn FR2677997A1 (fr) 1990-10-17 1992-08-13 Immunoglobuline purifiee.

Country Status (29)

Country Link
US (1) US5644036A (2)
EP (1) EP0504363B2 (2)
JP (1) JP2638680B2 (2)
KR (2) KR960015399B1 (2)
AT (2) ATA900791A (2)
AU (3) AU658926B2 (2)
BE (1) BE1004226A5 (2)
BR (1) BR1100358A (2)
CA (1) CA2069481C (2)
CH (2) CH681305A5 (2)
DE (1) DE69128774T3 (2)
DK (1) DK0504363T4 (2)
ES (2) ES2112865T5 (2)
FI (2) FI110003B (2)
FR (2) FR2668164A1 (2)
GB (2) GB9022547D0 (2)
GR (3) GR910100425A (2)
HU (1) HUT64601A (2)
IE (1) IE913560A1 (2)
IL (3) IL99761A0 (2)
IT (1) IT1250064B (2)
LU (1) LU88122A1 (2)
MX (1) MX9203794A (2)
MY (2) MY136210A (2)
NZ (2) NZ244114A (2)
PT (2) PT99248B (2)
TW (1) TW283710B (2)
WO (1) WO1992007084A1 (2)
ZA (2) ZA918259B (2)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
IL103418A (en) * 1991-10-15 1997-11-20 Wellcome Found Therapeutic agent for the t-cell mediated inflammation of the joints and its production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
CN1122531C (zh) † 1995-08-01 2003-10-01 巴斯德梅诺血清和疫苗公司 抗日本脑炎疫苗的工业生产方法和所获得的疫苗
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
WO2002072615A1 (en) * 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
ES2321539T3 (es) * 2001-06-05 2009-06-08 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
BRPI0417993A (pt) * 2003-12-22 2007-04-27 Genzyme Corp anticorpo anti-cd52 para tratamento da diabetes
EP1869065B1 (en) * 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
EP3345620B1 (en) 2009-05-13 2024-08-28 Genzyme Corporation Methods and compositions for treating lupus
EP2519536A4 (en) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MX2016008498A (es) 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3031028C (en) 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
US20220177518A1 (en) 2019-03-29 2022-06-09 Asahi Kasei Medical Co., Ltd. Method for purifying protein
CN113692420B (zh) 2019-04-08 2023-09-12 旭化成医疗株式会社 用于纯化含蛋白质的溶液的聚酰胺介质及其制造方法
US20220213140A1 (en) 2019-04-10 2022-07-07 Chugai Seiyaku Kabushiki Kaisha Method for purifying fc region-modified antibody
JPWO2022260091A1 (2) 2021-06-10 2022-12-15

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
JP3121823B2 (ja) * 1988-02-12 2001-01-09 ビーティージー・インターナショナル・リミテッド 抗体におけるまたは抗体に関する改良

Also Published As

Publication number Publication date
ZA918259B (en) 1993-04-16
AU658926B2 (en) 1995-05-04
JPH05504579A (ja) 1993-07-15
JP2638680B2 (ja) 1997-08-06
CH681305A5 (2) 1993-02-26
KR960015399B1 (ko) 1996-11-13
CA2069481C (en) 2003-07-29
EP0504363B1 (en) 1998-01-21
PT100988B (pt) 1999-08-31
AU4521897A (en) 1998-02-12
MY119030A (en) 2005-03-31
ITRM910788A1 (it) 1993-04-16
PT99248B (pt) 1999-04-30
ZA926191B (en) 1993-04-16
FI110003B (fi) 2002-11-15
PT99248A (pt) 1993-06-30
GR910100425A (el) 1992-09-25
PT100988A (pt) 1994-02-28
ATE162552T1 (de) 1998-02-15
BE1004226A5 (fr) 1992-10-13
ITRM910788A0 (it) 1991-10-16
GR920100471A (el) 1994-06-30
GR3026588T3 (en) 1998-07-31
DE69128774T2 (de) 1998-06-04
HU9202000D0 (en) 1992-10-28
FI110002B (fi) 2002-11-15
AU7024294A (en) 1995-01-05
FR2677997A1 (fr) 1992-12-24
FI922380L (fi) 1992-05-25
CA2069481A1 (en) 1992-04-18
IL102726A (en) 2002-08-14
GB2253397A (en) 1992-09-09
NZ244114A (en) 1995-06-27
BR1100358A (pt) 2000-03-28
CH681455A5 (2) 1993-03-31
IT1250064B (it) 1995-03-30
AU2532192A (en) 1993-02-11
IE913560A1 (en) 1992-04-22
AU649078B2 (en) 1994-05-12
TW283710B (2) 1996-08-21
WO1992007084A1 (en) 1992-04-30
DK0504363T3 (da) 1998-09-21
KR920703108A (ko) 1992-12-17
DK0504363T4 (da) 2007-05-29
LU88122A1 (fr) 1993-03-15
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
NZ240247A (en) 1994-03-25
DE69128774D1 (de) 1998-02-26
ATA900791A (de) 1996-06-15
HUT64601A (en) 1994-01-28
FR2668164B1 (2) 1995-04-14
ES2081742B1 (es) 1996-10-01
EP0504363B2 (en) 2007-02-07
FI922824L (fi) 1992-06-17
GB9022547D0 (en) 1990-11-28
IL102726A0 (en) 1993-01-31
FI922380A0 (fi) 1992-05-25
US5644036A (en) 1997-07-01
ES2081742A1 (es) 1996-03-01
ES2112865T5 (es) 2007-09-16
IL99761A0 (en) 1992-08-18
KR100193314B1 (ko) 1999-06-15
AU716402B2 (en) 2000-02-24
MX9203794A (es) 1992-07-01
ES2112865T3 (es) 1998-04-16
MY136210A (en) 2008-08-29
FI922824A0 (fi) 1992-06-17
GB9209529D0 (en) 1992-07-01
EP0504363A1 (en) 1992-09-23

Similar Documents

Publication Publication Date Title
BE1004226A5 (fr) Immunoglobuline purifiee.
JP2881499B2 (ja) 安定化抗体
US8105594B2 (en) Methods for amyloid removal using anti-amyloid antibodies
IE84931B1 (en) Purified IgG Antibodies
EP1078005A1 (en) Methods for amyloid removal using anti-amyloid antibodies
US8101155B2 (en) Sequence of STRO-1 antibody variable region
US20040234521A1 (en) Polyclonal populations of bispecific molecules and methods of production and uses thereof
AU649078C (en) Purified CDW52-specific antibodies
WO2024117938A1 (ru) Способы получения биоконъюгатов для печень-специфической направленной модуляции протеома
JPH0779795A (ja) ヒトモノクローナル抗体産生株の製造法
OA20246A (en) Monoclonal antibodies against the beta chain region of human TRBV9.
FR2652747A1 (fr) Application d'agents actifs pour la preparation d'un medicament destine au traitement de maladies auto-immunes.
HK1240247A1 (en) Anti‐transthyretin antibodies
HK1240247B (en) Anti‐transthyretin antibodies

Legal Events

Date Code Title Description
ST Notification of lapse